FDA Approves Drug to Fight Alzheimer’s:
Leqembi targets and reduces amyloid beta plaque in the brain, which slows progression of the disease. The Centers for Medicare and Medicaid has previously said it would pay for the drug — at a cost of $26,500 per year — upon full authorization.